Hydreight Announces Normal Course Issuer Bid
Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE:SO6), a mobile clinical network and medical platform operating across 50 U.S. states, has announced its intention to initiate a normal course issuer bid (NCIB). The company plans to repurchase up to 1,378,633 of its common shares, representing approximately 3.42% of outstanding shares and 10% of its public float.
The NCIB will commence on October 4, 2024, and conclude on October 3, 2025, unless completed earlier. Research Capital will conduct the bid on behalf of Hydreight. Purchases will be made on the open market through the TSX Venture Exchange, with the company paying the prevailing market price at the time of purchase. The repurchase will be funded from existing working capital.
Hydreight believes this move may contribute to an orderly market and is in the best interests of the company and its shareholders. The company may purchase shares if it believes they are trading at a price that doesn't adequately reflect Hydreight's business prospects, growth, and financial position.
Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE:SO6), una rete clinica mobile e piattaforma medica che opera in 50 stati americani, ha annunciato la sua intenzione di avviare un'offerta di acquisto nel corso normale (NCIB). L'azienda prevede di riacquistare fino a 1.378.633 delle sue azioni ordinarie, che corrispondono a circa 3,42% delle azioni in circolazione e 10% del flottante pubblico.
L'NCIB inizierà il 4 ottobre 2024 e si concluderà il 3 ottobre 2025, a meno che non venga portata a termine prima. Research Capital condurrà l'offerta per conto di Hydreight. Gli acquisti saranno effettuati sul mercato aperto tramite il TSX Venture Exchange, con l'azienda che pagherà il prezzo di mercato corrente al momento dell'acquisto. Il riacquisto sarà finanziato tramite il capitale circolante esistente.
Hydreight crede che questa mossa possa contribuire a un mercato ordinato ed essere nel migliore interesse dell'azienda e dei suoi azionisti. L'azienda potrebbe acquistare azioni se ritiene che stiano negoziando a un prezzo che non rifletta adeguatamente le prospettive di business, la crescita e la situazione finanziaria di Hydreight.
Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE:SO6), una red clínica móvil y plataforma médica que opera en 50 estados de EE.UU., ha anunciado su intención de iniciar una oferta pública de adquisición normal (NCIB). La empresa planea recomprar hasta 1,378,633 de sus acciones ordinarias, lo que representa aproximadamente 3.42% de las acciones en circulación y 10% de su flotación pública.
La NCIB comenzará el 4 de octubre de 2024 y concluirá el 3 de octubre de 2025, a menos que se complete antes. Research Capital llevará a cabo la oferta en nombre de Hydreight. Las compras se realizarán en el mercado abierto a través de la Bolsa de Valores de TSX Venture, con la empresa pagando el precio de mercado prevalente en el momento de la compra. La recompra se financiará con el capital de trabajo existente.
Hydreight considera que este movimiento puede contribuir a un mercado ordenado y está en el mejor interés de la empresa y sus accionistas. La empresa puede comprar acciones si cree que están cotizando a un precio que no refleja adecuadamente las perspectivas comerciales, el crecimiento y la situación financiera de Hydreight.
Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE:SO6)는 미국 50개 주에서 운영되는 모바일 클리니컬 네트워크이자 의료 플랫폼으로, 정상적인 매입 제안(NCIB)을 시작할 계획이라고 발표했습니다. 회사는 1,378,633주의 보통주를 재매입할 계획입니다, 이는 약 발행주식의 3.42%와 공공 플로트의 10%에 해당합니다.
NCIB는 2024년 10월 4일에 시작되어 2025년 10월 3일에 종료됩니다, 조기 완료될 경우는 예외입니다. Research Capital이 Hydreight를 대신하여 입찰을 진행할 것입니다. 구매는 TSX 벤처 거래소를 통해 공개 시장에서 이루어지며, 회사는 구매 시점의 시장 가격을 지불합니다. 재매입은 기존 운영 자본에서 자금을 조달합니다.
Hydreight는 이 조치가 시장의 질서를 유지하는 데 기여하고 회사와 주주에게 최선의 이익이 될 것이라고 믿습니다. 회사는 주식이 Hydreight의 비즈니스 전망, 성장 및 재무 상태를 적절히 반영하지 않는 가격에 거래되고 있다고 판단하면 주식을 구매할 수 있습니다.
Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE:SO6), un réseau clinique mobile et plateforme médicale opérant dans 50 états américains, a annoncé son intention de lancer une offre de rachat dans le cours normal des affaires (NCIB). La société prévoit de racheter jusqu'à 1 378 633 de ses actions ordinaires, représentant environ 3,42 % des actions en circulation et 10 % de son flottant public.
La NCIB commencera le 4 octobre 2024 et se terminera le 3 octobre 2025, sauf si elle est achevée plus tôt. Research Capital effectuera l'offre au nom de Hydreight. Les achats seront réalisés sur le marché ouvert par le biais de la Bourse de TSX Venture, la société payant le prix du marché courant au moment de l'achat. Le rachat sera financé par le capital de travail existant.
Hydreight estime que cette initiative pourrait contribuer à un marché ordonné et être dans le meilleur intérêt de l'entreprise et de ses actionnaires. L'entreprise peut acheter des actions si elle considère qu'elles se négocient à un prix qui ne reflète pas adéquatement les perspectives commerciales, la croissance et la situation financière de Hydreight.
Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE:SO6), ein mobiles klinisches Netzwerk und medizinische Plattform, die in 50 Bundesstaaten der USA tätig ist, hat seine Absicht angekündigt, ein reguläres Rückkaufprogramm (NCIB) zu starten. Das Unternehmen plant, bis zu 1.378.633 seiner Stammaktien zurückzukaufen, was etwa 3,42 % der ausgegebenen Aktien und 10 % des öffentlichen Streubesitzes entspricht.
Das NCIB wird am 4. Oktober 2024 beginnen und am 3. Oktober 2025 enden, es sei denn, es wird früher abgeschlossen. Research Capital wird das Angebot im Namen von Hydreight durchführen. Käufe werden an der offenen Markt über die TSX Venture Exchange getätigt, wobei das Unternehmen den zu diesem Zeitpunkt geltenden Marktpreis zahlt. Die Rückkäufe werden aus dem vorhandenen Betriebskapital finanziert.
Hydreight glaubt, dass dieser Schritt zu einem geordneten Markt beitragen und im besten Interesse des Unternehmens und seiner Aktionäre sein kann. Das Unternehmen kann Aktien erwerben, wenn es der Meinung ist, dass sie zu einem Preis gehandelt werden, der die Geschäftsaussichten, das Wachstum und die finanzielle Lage von Hydreight nicht angemessen widerspiegelt.
- Potential to improve shareholder value through share repurchases
- Company has sufficient working capital to fund the share buyback program
- Demonstrates management's confidence in the company's financial position and future prospects
- Reduction in cash reserves that could be used for business operations or growth initiatives
LAS VEGAS and VANCOUVER, British Columbia, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE:SO6) (the “Company”), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, announces today its intention to make a normal course issuer bid (the "Bid") to purchase for cancellation, from time to time, as it considers advisable, up to 1,378,633 of its issued and outstanding common shares, being approximately
The Bid will be conducted in accordance with applicable securities laws and the policies of the Exchange. Purchases will be made on the open market through the facilities of the Exchange. The price which the Company will pay for any shares purchased by it will be the prevailing market price of such common shares on the Exchange at the time of such purchase. The purchase of the common shares under the Bid is being funded from existing working capital.
In accordance with Exchange policies, the Company will include a summary of the Bid in the management information circular to be mailed to shareholders of the Company in respect of its next meeting of shareholders.
The Company believes that purchases of its common shares pursuant to the Bid may contribute to the facilitation of an orderly market and is in the best interests of the Company and its shareholders. In the event that the Company believes that its common shares begin trading in a price range that does not adequately reflect their underlying value based on the Company’s business prospects, growth and financial position, the Company may purchase common shares pursuant to the Bid.
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Contact
Email: ir@hydreight.com; Telephone: (480) 790 6886
Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements - This news release contains certain forward-looking statements, including statements regarding the Bid. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward looking statements, oral or written, made by itself or on its behalf, except as required by applicable law.
FAQ
How many shares does Hydreight Technologies (HYDTF) plan to repurchase in its normal course issuer bid?
When will Hydreight Technologies (HYDTF) start and end its share repurchase program?
Who will conduct the share repurchase program for Hydreight Technologies (HYDTF)?
How will Hydreight Technologies (HYDTF) fund its share repurchase program?
